Lung cancer drug response tied to tumor type: study
Testing lung cancer patients for tumor markers would enable doctors to choose which drug the patient is most likely to respond to, improving the chances for successful treatment, according to results from a recent trial.
Read more on Reuters via Yahoo! News
Ze-Guang Han and colleagues, at the Chinese National Human Genome Center at Shanghai, People’s Republic of China, have now identified SCARA5 as a candidate tumor suppressor gene in human hepatocellular carcinoma (HCC), a form of liver cancer that is the fifth most common cancer worldwide.
The research is reported in the Journal of Clinical Investigation.
» Read more: New Suppressor of Common Liver Cancer
FDA Approves Novel Prostate Cancer “Vaccine”
The treatment, which works by turning the body’s immune system against invading cancer cells, is called Provenge and is manufactured by Seattle biotech firm Dendreon
Read more on Time Magazine